Geschlechtsspezifische Aspekte bei der chronisch obstruktiven Lungenerkrankung

Boers E et al (2023) Global burden of chronic obstructive pulmonary disease through 2050. JAMA Netw Open 6:e2346598. https://doi.org/10.1001/jamanetworkopen.2023.46598

Gillissen A, Randerath W (2023) Weißbuch Lunge 2023 Bd. 5. Deutsche Gesellschaft für Pneumologie, Beatmungsmedizin e. V. und Deutsche Lungenstiftung e.V

Chapman KR, Tashkin DP, Pye DJ (2001) Gender bias in the diagnosis of COPD. Chest 119:1691–1695. https://doi.org/10.1378/chest.119.6.1691

Miravitlles M et al (2006) Attitudes toward the diagnosis of chronic obstructive pulmonary disease in primary care. Arch Bronconeumol 42:3–8. https://doi.org/10.1016/s1579-2129(06)60106-7

Akbarshahi H et al (2020) No gender-related bias in COPD diagnosis and treatment in Sweden: a randomised, controlled, case-based trial. ERJ Open Res. https://doi.org/10.1183/23120541.00342-2020

Somayaji R, Chalmers JD (2022) Just breathe: a review of sex and gender in chronic lung disease. Eur Respir Rev. https://doi.org/10.1183/16000617.0111-2021

Lutter JI et al (2020) Impact of education on COPD severity and all-cause mortality in lifetime never-smokers and longtime ex-smokers: results of the COSYCONET cohort. Int J Chron Obstruct Pulmon Dis 15:2787–2798. https://doi.org/10.2147/COPD.S273839

Stolz D et al (2022) Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet 400:921–972. https://doi.org/10.1016/s0140-6736(22)01273-9

(GOLD), G. I. f. C. O. L. D. Global Strategy For Prevention, Diagnosis And Management Of COPD: 2024 Report.

Carey MA et al (2007) The impact of sex and sex hormones on lung physiology and disease: lessons from animal studies. Am J Physiol Lung Cell Mol Physiol 293:L272–L278. https://doi.org/10.1152/ajplung.00174.2007

Tam A et al (2011) The role of female hormones on lung function in chronic lung diseases. BMC Womens Health 11:24. https://doi.org/10.1186/1472-6874-11-24

Joo J, Himes B (2021) Gene-based analysis reveals sex-specific genetic risk factors of COPD. AMIA Annu Symp Proc 2021:601–610

Alemayohu MA et al (2023) Burden and risk factors of chronic obstructive pulmonary disease in Sub-Saharan African countries, 1990–2019: a systematic analysis for the Global Burden of disease study 2019. EClinicalMedicine 64:102215. https://doi.org/10.1016/j.eclinm.2023.102215

Murgia N, Gambelunghe A (2022) Occupational COPD-The most under-recognized occupational lung disease? Respirology 27:399–410. https://doi.org/10.1111/resp.14272

Dumas O et al (2019) Association of occupational exposure to disinfectants with incidence of chronic obstructive pulmonary disease among US female nurses. JAMA Netw Open 2:e1913563. https://doi.org/10.1001/jamanetworkopen.2019.13563

Peters SA, Huxley RR, Woodward M (2014) Do smoking habits differ between women and men in contemporary Western populations? Evidence from half a million people in the UK Biobank study. Bmj Open 4:e5663. https://doi.org/10.1136/bmjopen-2014-005663

Sorheim IC et al (2010) Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax 65:480–485. https://doi.org/10.1136/thx.2009.122002

Prescott E, Bjerg AM, Andersen PK, Lange P, Vestbo J (1997) Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 10:822–827

Bhatt SP et al (2022) Sex differences in airways at chest CT: results from the COPDgene cohort. Radiology 305:699–708. https://doi.org/10.1148/radiol.212985

AWMF. S3-Leitlinie Nationale VersorgungsLeitlinie COPD, 〈www.leitlinien.de/copd. 〉 (2021).

DeMeo DL et al (2018) Women manifest more severe COPD symptoms across the life course. Int J Chron Obstruct Pulmon Dis 13:3021–3029. https://doi.org/10.2147/COPD.S160270

Raherison C et al (2014) Clinical characteristics and quality of life in women with COPD: an observational study. BMC Womens Health 14:31. https://doi.org/10.1186/1472-6874-14-31

Worth H et al (2016) The ‘real-life’ COPD patient in Germany: the DACCORD study. Respir Med 111:64–71. https://doi.org/10.1016/j.rmed.2015.12.010

Karch A et al (2016) The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med 114:27–37. https://doi.org/10.1016/j.rmed.2016.03.008

Jorres RA et al (2010) Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease—an overview of the cohort study COSYCONET. Dtsch Med Wochenschr 135:446–449. https://doi.org/10.1055/s-0030-1249185

Kahnert K et al (2023) What have we learned from the German COPD cohort COSYCONET and where do we go from here? Pneumologie 77:81–93. https://doi.org/10.1055/a-1966-0848

Kardos P et al Issues COPD 49:A1754–A1754

Trudzinski FC et al (2023) Gender-specific differences in COPD symptoms and their impact for the diagnosis of cardiac comorbidities. Clin Res Cardiol 112:177–186. https://doi.org/10.1007/s00392-021-01915-x

Trudzinski FC et al (2022) Sex-specific associations of comorbidome and pulmorbidome with mortality in chronic obstructive pulmonary disease: results from COSYCONET. Sci Rep 12:8790. https://doi.org/10.1038/s41598-022-12828-8

Divo M et al (2012) Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186:155–161. https://doi.org/10.1164/rccm.201201-0034OC

Lisspers K et al (2019) Gender differences among Swedish COPD patients: results from the ARCTIC, a real-world retrospective cohort study. Npj Prim Care Respir Med 29:45. https://doi.org/10.1038/s41533-019-0157-3

Jaramillo JD et al (2015) Reduced bone density and vertebral fractures in smokers. Men and COPD patients at increased risk. Ann Am Thorac Soc 12:648–656. https://doi.org/10.1513/AnnalsATS.201412-591OC

Rogliani P, Cavalli F, Ritondo BL, Cazzola M, Calzetta L (2022) Sex differences in adult asthma and COPD therapy: a systematic review. Respir Res 23:222. https://doi.org/10.1186/s12931-022-02140-4

Calverley PM et al (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775–789. https://doi.org/10.1056/NEJMoa063070

Antoniu SA (2009) UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. Evaluation of: Tashkin DP, Celli B, Senn S et al.: a 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 359(15):1543–1554. Expert Opin Pharmacother 10:719–722. https://doi.org/10.1517/14656560902740804

Vogelmeier C et al (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364:1093–1103. https://doi.org/10.1056/NEJMoa1008378

Wedzicha JA et al (2016) Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 374:2222–2234. https://doi.org/10.1056/NEJMoa1516385

Lipson DA et al (2018) Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 378:1671–1680. https://doi.org/10.1056/NEJMoa1713901

Rabe KF et al (2020) Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 383:35–48. https://doi.org/10.1056/NEJMoa1916046